Compare SEM & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEM | AUPH |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2009 | 1999 |
| Metric | SEM | AUPH |
|---|---|---|
| Price | $14.94 | $15.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $16.33 | ★ $17.25 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 02-19-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.87 | 0.55 |
| Revenue | ★ $5,368,760,000.00 | $265,808,000.00 |
| Revenue This Year | $5.53 | $21.76 |
| Revenue Next Year | $4.33 | $16.45 |
| P/E Ratio | ★ $19.68 | $28.76 |
| Revenue Growth | ★ 45.29 | 20.62 |
| 52 Week Low | $11.65 | $6.55 |
| 52 Week High | $20.83 | $16.54 |
| Indicator | SEM | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 55.71 |
| Support Level | $14.73 | $15.64 |
| Resistance Level | $15.18 | $16.54 |
| Average True Range (ATR) | 0.30 | 0.38 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 20.64 | 57.55 |
Select Medical Holdings Corp is a healthcare company that operates through three segments: critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics. Critical illness recovery hospitals which derives maximum revenue consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. The rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. The outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.